Through the BTS-Stroke activity, the rate for IV tPA use was significantly increased with nearly four-fold from 1.2% in 2006–08 to 4.6% in 2010–11, which was equivalent to the GWTG-Stroke program. The gene discussed is PLAT; the disease is Stroke.